<DOC>
	<DOCNO>NCT00624338</DOCNO>
	<brief_summary>This study evaluate efficacy safety atacicept compare placebo prevent new flare subject systemic lupus erythematosus ( SLE ) confirm optimal dose atacicept treatment subject SLE gain information effect atacicept marker specific mechanism action ( MoA ) correlation disease activity/progression . Study medication administer subcutaneous ( skin ) injection , begin twice weekly injection first 4 week , follow weekly dos 48 week . Following last treatment , safety follow-up period 24 week conduct .</brief_summary>
	<brief_title>Atacicept Phase 2/3 Generalized Systemic Lupus Erythematosus ( APRIL-SLE )</brief_title>
	<detailed_description />
	<mesh_term>Lupus Erythematosus , Systemic</mesh_term>
	<criteria>Male female 16 year age old Disease history least six month meet least 4 11 American College Rheumatology ( ACR ) criteria SLE Active SLE least one British Isles Lupus Assessment Group ( BILAG ) flare A B screening require change dose corticosteroid Positive antinuclear antibody ( ANA ) antidoublestranded deoxyribonucleic acid ( dsDNA ) screen Female subject must willing avoid pregnancy use adequate method contraception 4 week prior Study Day 1 , trial 24 week last dose study medication Other protocol define inclusion criterion could apply Active moderate severe glomerulonephritis ( kidney impairment ) define protocol Active central nervous system SLE deem severe/progressive and/or associate significant cognitive impairment lead inability provide inform consent and/or comply protocol Previous treatment rituximab , abatacept , belimumab History demyelinate disease multiple sclerosis ( MS ) optic neuritis Other protocol define exclusion criterion could apply</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>Atacicept 75 150 mg</keyword>
	<keyword>Placebo</keyword>
</DOC>